2026-03-30 05:15Summary of Conference Call Notes Industry Overview - The report focuses on the A-share Healthcare sector in China, particularly in the context of the ongoing Middle East crisis and its impact on supply chains and operations [1] Company-Specific Insights United Imaging (688271.SS) - Demand and Orderbook: The impact of the Middle East crisis on United Imaging's business is minimal, accounting for less than 2% of total revenue [2] - Operations: Liquid helium constitutes 10%-20% of MRI equipment production costs. Although prices have fluctuated due to the crisis, the company has secured its main helium sources, limiting immediate impact. Medium-term effects will be monitored [3] - Price Target and Risks: Rated as "Buy" with a 12-month target price of Rmb174, based on a DCF valuation. Key risks include chip supply chain issues, raw material risks (especially helium), macroeconomic downturns in China, and potential Value-Based Pricing (VBP) risks [11] SNIBE (300832.SZ) - Demand and Orderbook: Logistics issues have disrupted demand across the Middle East region [4] - Operations: Current operations remain unaffected as core raw materials can be self-produced or sourced locally [5] - Price Target and Risks: Rated as "Buy" with a 12-month target price of Rmb72. Risks include slower import substitution progress, policy risks (VBP and DRG/DIP), intensifying competition, distributor model risks, and new technology evolution [12] Kelun (002422.SZ) - Demand and Orderbook: The subsidiary Chuanning Bio, which produces antibiotic APIs, is unaffected in demand as customers are primarily in China and India. Other domestic businesses are also stable. The company can pass on cost increases to customers if necessary [9] - Operations: The primary fuel for antibiotic API production is coal, thus not affected. However, price fluctuations for organic solvents and petrochemical precursors have been noted, with alternative sources available. These items represent a low percentage of overall costs [10] - Price Target and Risks: Rated as "Neutral" with a 12-month target price of Rmb38. Risks include API price declines and increased control over infusion therapies at hospitals, while upside risks involve better-than-expected product delivery and sales ramp-up [13] Additional Insights - The report emphasizes the importance of monitoring supply chain risks due to geopolitical tensions, particularly in the Middle East, which could affect raw material costs and logistics for companies in the healthcare sector [1][4][5] - The companies mentioned have strategies in place to mitigate risks associated with supply chain disruptions, indicating a level of resilience in their operations [3][5][10] Conclusion - The A-share Healthcare sector in China is currently facing limited impact from the Middle East crisis, with companies like United Imaging, SNIBE, and Kelun demonstrating resilience through strategic sourcing and operational adjustments. However, ongoing monitoring of geopolitical developments and their potential effects on supply chains is crucial for future performance assessments [1][2][4][5][9][10]